Published in J Immunol on March 01, 1980
Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun (1981) 1.43
The Pathogenesis of Lupus Nephritis. J Clin Cell Immunol (2014) 0.93
Legionella pneumophila lipopolysaccharide activates the classical complement pathway. Infect Immun (1992) 0.86
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
Subcellular localization of pulmonary antiotensin-converting enzyme (kininase II). Biochem J (1975) 2.07
Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors. Infect Immun (1974) 1.99
Biosynthesis of the first component of complement by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1 subunits. J Immunol (1978) 1.79
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood (1995) 1.75
The separation of nine components and two inactivators of components of complement in humansserum. Immunochemistry (1970) 1.72
Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol (1974) 1.69
Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum (1990) 1.66
Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation (2001) 1.64
Antibody-independent interaction of the first component of complement with Gram-negative bacteria. Infect Immun (1978) 1.60
Complement-mediated fragmentation and lysis of opsonized platelets: ender differences in sensitivity. J Lab Clin Med (1994) 1.47
Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun (1981) 1.43
A 66-kilodalton heat shock protein of Salmonella typhimurium is responsible for binding of the bacterium to intestinal mucus. Infect Immun (1992) 1.41
Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem (1996) 1.35
Fc and C3b receptors on pulmonary endothelial cells: induction by injury. Science (1981) 1.31
Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus (2010) 1.28
Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol (2000) 1.25
Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation (1997) 1.23
[Measurement of complement with a microliter method]. Z Med Mikrobiol Immunol (1969) 1.22
Immunologically-mediated renal disease in Waldenström's macroglobulinemia. Am J Med (1975) 1.21
Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum (1988) 1.20
Complement-mediated release of histamine from human leukocytes. J Immunol (1975) 1.20
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry (1976) 1.20
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--I. Effect on fluid phase C1 and on C1 bound to EA or to EAC4. Immunochemistry (1976) 1.20
Interactions between mycoplasma pneumoniae and the first components of complement. Infect Immun (1977) 1.17
Immunoblastic lymphadenopathy with mixed cryoglobulinemia. A detailed case study. N Engl J Med (1975) 1.15
Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells. J Immunol (2001) 1.14
Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med (1987) 1.14
Specific antibodies directed against toxins of Ptychodiscus brevis (Florida's red tide dinoflagellate). Toxicon (1984) 1.11
PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer (2010) 1.11
Inflammation in areas of remote changes following focal brain lesion. Prog Neurobiol (2005) 1.11
Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol (2000) 1.11
vacA genotypes and genetic diversity in clinical isolates of Helicobacter pylori. Clin Diagn Lab Immunol (1998) 1.10
Modified immunoassays for polyether toxins: implications of biological matrixes, metabolic states, and epitope recognition. J AOAC Int (1995) 1.07
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--II. Effect of polyanions on the binding of C2 to EAC4b. Immunochemistry (1976) 1.07
Brevetoxin PbTx-2 immunology: differential epitope recognition by antibodies from two goats. Toxicon (1994) 1.05
Role of C1q in phagocytosis of Salmonella minnesota by pulmonary endothelial cells. Infect Immun (1989) 1.05
Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera. Immunology (1980) 1.05
Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol (1999) 1.03
Antibody-independent killing of gram-negative bacteria via the classical pathway of complement. Immunol Lett (1987) 1.03
Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis. J Neurol Sci (1995) 0.99
M proteins of group G streptococci: mechanisms of resistance to phagocytosis. J Infect Dis (1995) 0.98
Lupus nephritis: a clinical review for practicing nephrologists. Clin Nephrol (2002) 0.98
The alteration of endotoxin by postheparin plasma and purified fractions. II. Relationship of the endotoxin detoxifying activity of euglobulin from postheparin plasma to lipoprotein lipase. J Immunol (1967) 0.97
In vitro chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSC 293015). Eur J Cancer Clin Oncol (1987) 0.97
Evidence for direct binding of the first component of complement, C1, to outer membrane proteins from Salmonella minnesota. Curr Top Microbiol Immunol (1985) 0.97
Antibody-independent binding of complement component C1q by Legionella pneumophila. Infect Immun (1995) 0.96
Biosynthesis of the collagen-like C1q molecule and its receptor functions for Fc and polyanionic molecules on macrophages. Curr Top Microbiol Immunol (1983) 0.95
Endothelial cells of bovine pulmonary artery lack receptors for C3b and for the Fc portion of immunoglobulin G. Science (1980) 0.95
Interaction of purified lipoteichoic acid with the classical complement pathway. Infect Immun (1986) 0.94
Heat shock (stress) proteins and autoimmunity in rheumatic diseases. Semin Arthritis Rheum (1993) 0.94
The role of accessory cells in polyclonal T cell activation. I. Both induction of interleukin 2 production and of interleukin 2 responsiveness by concanavalin A are accessory cell dependent. Eur J Immunol (1983) 0.94
Requirement for an additional serum factor essential for the antibody-independent activation of the classical complement sequence by Gram-negative bacteria. Infect Immun (1982) 0.93
High-throughput phenotyping of avoidance learning in mice discriminates different genotypes and identifies a novel gene. Genes Brain Behav (2012) 0.93
Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J Immunol (1982) 0.92
Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains. Genes Brain Behav (2006) 0.92
Tumor-associated antigen in human pancreatic cancer. J Natl Cancer Inst (1979) 0.91
IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin Exp Immunol (2000) 0.91
Inactivation of C1 in rheumatoid synovial fluid, purfied C1 and C1 esterase, by gold compounds. Clin Exp Immunol (1974) 0.91
Activation of the first component of complement evidence for an internal activation step. J Immunol (1972) 0.91
Complement activation and corticosteroid therapy in the development of the adult respiratory distress syndrome. Chest (1987) 0.90
The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes. Prog Allergy (1982) 0.89
Immunological characterization of two major proteins isolated from the outer membrane of Proteus mirabilis. Infect Immun (1980) 0.89
The role of the classical pathway for the bactericidal effect of normal sera against gram-negative bacteria. Curr Top Microbiol Immunol (1985) 0.89
Autoantibodies to the collagenous region of C1q occur in three strains of lupus-prone mice. Clin Exp Immunol (1996) 0.89
The influence of chrysotherapy on serum protein and immunoglobulin levels, rheumatoid factor, and antiepithelial antibody titers. J Lab Clin Med (1975) 0.89
Ultracentrifugation studies on the native form of the first component of human complement (C1). FEBS Lett (1976) 0.89
The first component of complement in serum: evidence for a hitherto unrecognized factor in C1 necessary for internal activation. J Immunol (1973) 0.88
The functions of endogenous C1q, a subcomponent of the first component of complement, as a receptor on the membrane of macrophages. Mol Immunol (1982) 0.88
Gene expression of the A- and B-chain of mouse C1q in different tissues and the characterization of the recombinant A-chain. J Immunol (1991) 0.88
Clinical and immunological studies in a case of selective complete C1q deficiency. Clin Exp Immunol (1979) 0.88
Expression of membrane C1q in human monocyte-derived macrophages is developmentally regulated and enhanced by interferon-gamma. FEBS Lett (2001) 0.87
Inhibition of the eighth component of complement (C8) by ethylenediaminetetra-acetate (EDTA). J Immunol (1970) 0.86
Legionella pneumophila lipopolysaccharide activates the classical complement pathway. Infect Immun (1992) 0.86
Contributions of C1q, bacterial lipopolysaccharide, and porins during attachment and ingestion phases of phagocytosis by murine macrophages. Infect Immun (1986) 0.86
Collagen-like complement component C1q is a membrane protein of human monocyte-derived macrophages that mediates endocytosis. J Immunol (1995) 0.85
Alpha-fetoprotein and carcinoembryonic antigen in a case of gastric carcinoma metastatic to the liver. Am J Dig Dis (1973) 0.85
The Cl inactivator from guinea pig serum. 3. Characterization and kinetic data of the reaction between the inactivator and EACl and EACl4. Immunochemistry (1972) 0.85
The secretion of fibrinolysin by cultured rat ovarian tumor cells. Biochem Biophys Res Commun (1973) 0.85
Evidence that C1s participates in the alternative complement pathway. Int Arch Allergy Appl Immunol (1976) 0.85
Purification and characterization of human, guinea pig and mouse C1q by fast protein liquid chromatography (FPLC). J Immunol Methods (1984) 0.84
Molecular cloning and characterization of the complementary DNA coding for the B-chain of murine Clq. FEBS Lett (1989) 0.84
Receptor-mediated binding of C1q on pulmonary endothelial cells. Tissue Cell (1986) 0.84
The alteration of endotoxin by postheparin plasma and its purified fractions. I. Comparison of the ability of guinea pig postheparin and normal plasma to detoxify endotoxin. J Immunol (1967) 0.84
Complement components C1q, C1r/C1s, and C1INH in rheumatoid arthritis. Correlation of in situ hybridization and northern blot results with function and protein concentration in synovium and primary cell cultures. Arthritis Rheum (1995) 0.84
Complement activation in septic shock patients. Crit Care Med (1986) 0.84
MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer (2000) 0.84
Non-sense and missense mutations in the structural genes of complement component C1q A and C chains are linked with two different types of complete selective C1q deficiencies. J Immunol (1995) 0.83
Electron microscopic study showing antibody-independent binding of C1q, a subcomponent of the first component of complement, to serum-sensitive salmonellae. Infect Immun (1984) 0.83
Insoluble polyanions as activators of both pathways of complement. Immunology (1977) 0.83
The first component of human complement: on the mechanism of activation by some carbohydrates. J Immunol (1981) 0.83
Functional domains of the human C1q A-chain. Behring Inst Mitt (1993) 0.83
Immunofluorescence studies on the subcomponents of the first component of complement (C1): detection of C1q and C1s in different cells of biopsy material and on human as well as on guinea pig peritoneal macrophages. Immunobiology (1981) 0.83